Targeting Host Cell Surface Nucleolin for RSV Therapy: Challenges and Opportunities

Nucleolin (NCL) has been reported as a cellular receptor for the human respiratory syncytial virus (RSV). We studied the effects of re-purposing AS1411, an anti-cancer compound that binds cell surface NCL, as a possible novel strategy for RSV therapy in vitro and in vivo. AS1411 was administered to...

Descripción completa

Detalles Bibliográficos
Autores principales: Mastrangelo, Peter, Norris, Michael J., Duan, Wenming, Barrett, Edward G., Moraes, Theo J., Hegele, Richard G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620558/
https://www.ncbi.nlm.nih.gov/pubmed/28925950
http://dx.doi.org/10.3390/vaccines5030027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620558/
https://www.ncbi.nlm.nih.gov/pubmed/28925950
http://dx.doi.org/10.3390/vaccines5030027

Ejemplares similares